X-Vax Technology Appoints Varsha K. Jain, MD as Chief Clinical Development Officer
PALM BEACH GARDENS, Fla., July 21, 2021 /PRNewswire/ -- X-Vax Technology, Inc. (X-VAX), a biotechnology company developing vaccines based on a new approach that mediates the killing of infected cells, today announced the appointment of Varsha K. Jain, MD as Chief Clinical Development Officer.
- PALM BEACH GARDENS, Fla., July 21, 2021 /PRNewswire/ -- X-Vax Technology, Inc. (X-VAX), a biotechnology company developing vaccines based on a new approach that mediates the killing of infected cells, today announced the appointment of Varsha K. Jain, MD as Chief Clinical Development Officer.
- Previously, Dr. Jain served as Senior Program Officer, Vaccine Development and Surveillance at the Bill and Melinda Gates Foundation.
- Earlier in her career, she oversaw influenza, herpes and Lyme disease vaccine programs in Global Vaccine Discovery and Development at GlaxoSmithKline (GSK).
- Reporting to Varsha K. Jain, MD will be Guissou Dabiri, PhD, who joined X-VAX as Head of Scientific Communications, and Michael Schwartz, Head of Clinical Trials Management.